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9General introduction 
Colorectal cancer  
Cancer develops through accumulation of several different genetic changes in the cell. The 
suggestion that cancer was a genetic disorder in somatic cells, was first presented in the end 
of the last 19th century by Hansemann [1]. Some years later in 1914 Boveri [2] proposed 
that chromosome abnormalities were fundamental to the development of cancer. During the 
last decade, numerous studies have been published, showing that several oncogenes, 
tumour-supressor and repair genes are important in colorectal cancer. These genes have an 
important impact as prognostic factors in colorectal cancer, and may also be essential to 
improved treatment and outcome for the patient.  
Colorectal cancer is one of the most common malignant diseases in the Western countries, 
and increased incidence has been observed over the past decades [3]. In the Norwegian 
population, the Cancer Registry of Norway Institute of Population-based Cancer Research 
recorded 3482 new cases of colon (2345) and rectum (1137) cancer in 2004 [4]. Cancer in 
the colon- and rectum compose 15% of all the new cancer cases, and is the most prevalent 
cancer site within the Norwegian population. Rectal cancer has a male/female incidence 
ratio of 1.5, while colon cancer has a male/female ratio incidence of 1.1 [4]. Cancer in the 
colon and the rectum mostly affect the elderly and the age specific incidence of rectal cancer 
increases sharply after the age of 50 years [5]. Some factors contribute to the increased risk 
of colon and rectal cancer. Familial Adenomatous Polyposis (FAP) is one of the known 
autosomal dominant inherited colorectal cancer (CRC) diseases, but accounts for less than 
1% of all cases. This is a disease recognised by formation of polyposis at a young age [6]. 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome is 
another autosomal dominant cancer syndrome and is the most common form of hereditary 
colorectal cancer accounting for as much as 5 % of all CRCs [7]. HNPCC typically 
develops around the age of 45. Another factor causing increased risk of colon and rectum 
cancer is chronic inflammatory diseases such as Ulcerative colitis and Crohns disease [8]. 
Patients that have received pelvic radiation in association with gynaecological cancers have 
been observed to have an increased risk 2-3 times compared to that of a normal population 
[9].
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Treatment and outcome 
The choice of treatment for colorectal cancer is dependent on the tumour stage at diagnosis. 
Surgery is the main and most efficient treatment for colorectal cancer and most of the 
patients with primary tumours and local recurrences will have their tumour removed. Early 
detection of colorectal cancer is correlated with high survival rates, as 90% of patients 
diagnosed with TNM stage 1 tumours are alive 5 years after the initial diagnosis, compared 
to a steady decrease in 5-year survival rates in later stages, down to 10% in stage IV patients 
[10].
Patients with advanced local, regional or metastatic cancer require additional therapy, 
consisting of chemotherapy and radiation. In Norway, 5-fluorouracil (5-FU) in combination 
with calsiumfolinate used to be the standard chemotherapy for this patient group. Later 
Oxaliplatin has been added to this first line chemotherapy. 
 Radiation has a major role in the treatment of rectal cancers. Radiation can be given before 
surgery to cause the tumour to shrink allowing easier removal, or postoperatively to 
decrease the risk of cancer recurrence. Tumour extension and dissemination are the most 
important prognostic factors. In spite of what is believed to be a curative tumour resection 
Figure 1. The distribution of cancer types in Norway (2004). This was obtained from the 
Norwegian Cancer Registry [4].
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many patients later suffer from metastases or tumour recurrence. Possible causes of local 
recurrences are believed to be; incomplete resection of the primary carcinoma [11], 
insufficient removal of involved regional lymphatic vessels or nodes [12], implantation of a 
secondary tumour near the suture line and exfoliated colorectal cancer cells released during 
the surgical procedure [13].
Survival from rectal cancer has been continuously improved during the past decades. The 
main reason for this seems to be the development of the surgical technique called total 
mesorectal excision (TME) [14;15]. An additional local national contributing factor was the 
establishment of The Rectum Cancer Registry at The Cancer Registry of Norway [4;16]. 
The main element in this initiative was an educational program to standardize and optimize 
surgery for rectal cancer at a national level. At the same time pathologists were educated in 
the optimal principles of handling and describing rectal cancer specimens. All surgical 
departments treating rectal cancer were invited to transfer their clinical data to this registry. 
Each department regularly receives its own results together with the national average for 
comparison and quality control. 
Genetic model for colorectal cancer 
Colorectal adenoma-carcinoma sequence model  
Development of colorectal cancer occurs through a number of genetic and epigenetic 
changes, and was described as an adenoma–carcinoma sequence in 1975 by Muto et al. [17].  
Almost twenty years later these stages were used in a genetic model put forward by Fearon 
and Vogelstein in 1990 [18]. This model describes the stepwise progression from normal to 
dysplastic epithelium to carcinoma associated with multiple genetic alterations. The authors 
stressed that mutations in at least four to five regions, including Adenomatous Polyposis 
Coli (APC), Kirsten RAS gene (k-ras), deleted in colorectal cancer (DCC) and Tumour 
protein gene p53 (TP53) were required for formation of a malignant colorectal tumour. 
Further studies have shown that the order of genetic events is essential [19;20]. This concept 
not only provides an excellent model to study the genesis of invasive cancer, but also offers 
a means of preventing colorectal cancer by endoscopic removal of precursor lesions. 
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Differences between the left- and the right side of colon 
CRC’s that arise proximal (right) or distal (left) are different with respect to 
epidemiological, clinicopathological, biochemical as well as genetic factors [21]. This lead 
to the suggestion that proximal and distal tumours follow broadly different molecular 
pathways in carcinogenesis. Two distinct pathways have been identified which result in 
colorectal cancer. The tumour suppressor pathway, also termed the chromosomal instability 
pathway (CIN), account for 85% of the colorectal carcinomas and most sporadic 
carcinomas. The CIN pathway is characterized by loss and gains of chromosomes 
(aneopleoidy) often 5q, 17p and 18q as well as loss of heterozygozity (LOH), which is a 
loss of one of the parental alleles present in cells, and mutations in p53. The CIN pathway 
most often appears in the distal part of the colon. 
The second mutational pathway, the microsatelitte instability (MIN) pathway accounts for 
the remaining 15% of colorectal carcinomas [22]. This pathway often has a family history of 
colorectal cancer suggesting a genetic contribution or common environmental exposure 
among family members, or a combination thereof. Existence of multiple alternative genetic 
pathways have been suggested [23;24]. The MIN pathway is characterized by defects in the 
mismatch repair systems, leading to downstream mutations in genes such as TGFBR2 
(transforming growth factor-E) [25], BAX (BCL2-associated X protein) [26], k-ras (Kirsten 
RAS gene), APC (adenomatosis polyposis coli) [27] and candidate target genes such as 
WISP-3 [28]. Tumours with MIN have some clinicopathological features in common, like 
proximal location in the colon [29]. MIN are also more likely to be present at an advanced 
age [30] and to be associated with female gender [31].    
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Differences between rectum and colon
Colon and rectal cancers were previously considered a common entity, but are now regarded 
as different diseases with a number of common components. Rectal carcinomas are assumed 
to arise through similar mechanisms as in distal colon tumours (descending and sigmoid 
colon). It is therefore not surprising that significant differences in rectal and colon 
carcinomas with respect to age and gender of the patient have been reported [34-36]. 
Breivik et al [36], showed that proximal and distal colorectal cancers evolve by different 
genetic pathways and that these pathways are influenced by sex-related factors. Frattini et 
al.[37] did a study on different genetic features associated with colon and rectal 
carcinogenesis. The different pathways observed and their distribution were summarized as 
followed; the number of k-ras mutations detected were significantly higher in colon than 
rectal tumours, and a mutational pattern restricted to the APC gene was more common in 
rectal than in colon tumours. According to Kapiteijn et al. [34] the p53 pathway seems to be 
more important in rectal cancer than in colon cancer, and also reported a correlation of p53 
with reduced disease free survival in rectal cancer, but not in colon cancer. It is well known 
that the clinical behaviour of colon cancer and rectal cancer is different. In rectal cancer 
local recurrences is a major problem, whereas in colon cancer distant metastasis and 
Figure 2. Genetic and epigenetic changes in the adenoma-carcinoma sequence in left versus right-
sided carcinogenesis. Modified after [32-33]. 
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carsinomatosis are the most important problems. This again suggests that the cause factors 
and the molecular basis may differ between colon and rectal cancer. When prognostics 
markers are investigated in larger series, such differences in ethiology and biological 
behaviour between colon and rectal cancer should be considered. 
Peritoneal cavity 
The peritoneum is a serous abdominal membrane, which lines both the abdominal wall and 
the intra-abdominal viscera. Although the sheet of body tissue ultimately forms one 
continuous sheet, two types or layers of peritoneum are usually referenced to as well as the 
potential space between them: The outer layer, called the parietal peritoneum, is attached to 
the abdominal wall. The inner layer, the visceral peritoneum, is more or less wrapped 
around the internal organs located inside the abdominal cavity. The potential space between 
these two layers is the peritoneal cavity [38]. The term mesentery is often used to refer to a 
double layer of visceral peritoneum. Blood vessels, lymphnodes and nerves are located 
between these layers. It should be noted that the space between these two mesenterial layers 
is technically outside of the peritoneal sac, and not within the peritoneal cavity see Figure 3.
Figure 3. This picture show horizontal disposition of the peritoneum in the lower part of the abdomen. 
http://education.yahoo.com/reference/gray/illustrations/figure?id=1038 (This figure has a GNU Free 
Documentation License). 
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The initial dissemination of rectal cancer tumours cells occurs through three routes: lymphs, 
portal blood, and peritoneal surfaces. Although lymphatic and hematogenous metastases 
indicate an aggressive disease process, it is possible that dissemination to the peritoneal 
surfaces may be the result of direct contamination with cancer cells of the parietal and 
visceral peritoneum. This suggests that viable tumour cells with proliferative and perhaps 
metastatic potential had been shed from the primary tumour site either before removal of the 
tumour or during surgical resection [39]. Patients with overt peritoneal or local metastases 
from colorectal cancer have a poor prognosis [40]. However, aggressive treatments by 
surgery and infusion of intra-peritoneal chemotherapy have been tried and appear to benefit 
selected patients [41]. 
Histopatholgically stages 
The goal of staging is to determine the extent and location of the tumour in order to develop 
appropriate treatment strategies. The staging of rectal cancer closely approximates the 
staging of colon cancer. Dukes staging was introduced in 1932 [42] to characterise the 
extent of tumour dissemination. This placed the cancer into one of three categories (Stages 
A, B, C). Later the system was modified to include a fourth stage (Stage D) [43]. Many 
other staging systems have been proposed trying to define a scheme which is more 
predictive, e.g. The Gunderson-Sosin modification of the Astler-Coller system [44] and Jass 
et al. [45]. More recently, the American Joint Committee on Cancer (AJCC) has introduced 
the TNM staging system, which places the cancer into one of four stages (Stages I-IV) [46]. 
Listed below in Table 1 are the Duke and TNM staging systems.  
Dukes’
Stages
Disease
type Stage
TNM staging 
T                   N                        M
A Local I T1, T2 N0 M0 
B Local II T3-T4 N0 M0 
C Regional III T1-T4 N1-N2 M0 
D Distant IV T1-T4 N1-N2 M1 
Table 1. This table show TNM staging. T1-4; the increasing spread of primary 
tumour, N; Lymph node metastasis, M; distant metastasis. 
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In addition to the TNM staging the resection margins of the tumour are also an important 
part of the staging procedure. It has been shown that the distance from the tumour to the 
circumferential resection margin is the most powerful predictor for local recurrence and not 
the T stage [47;48]. The local surgical achievements are staged as follows: R0 
microscopically free circumferential and distal margins, R1 microscopically involved 
margins, and R2 locally macroscopic residual cancer or no resection. 
Figure 4. Shows the different TNM stages of colorectal cancer. This figure is reproduced from the 
National Cancer Institute 
http://www.cancer.gov/cancertopics/pdq/treatment/rectal/Patient/page2#Keypoint7.
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Signal pathways and biological markers 
Selected genes from three signalling pathways have a central role in this thesis. The first one 
is the Ras-pathway with the MAPK-kinase pathway. One major function of the ras protein 
family is to couple growth factors to the Raf-mitogen-activated protein (MAP) kinase 
kinase-MAP kinase signal transduction pathway, which leads to the nuclear expression of 
early response genes. The mutated k-ras product maintains a prolonged state of activation 
leading to cellular proliferation. Mutations in k-ras is described as an early event in the 
process of colorectal carcinogenesis [18]. Another important pathway is the TP53-BAX 
pathway, which is shown to be responsible for the progression of the colorectal tumour [19]. 
The last pathway described in this thesis is the folate metabolism. This metabolism is 
thought to contribute to colorectal carcinogenesis by altering both DNA methylation and 
nucleotide synthesis. Genes coding for metabolism enzymes, receptor proteins or protein 
target of chemotherapy agents often present different genetic polymorphisms able to 
influence drug sensitivity, toxicity and dosing [49]. 
Ras-pathway with the MAPK-kinase pathway 
A large number of oncogenes have been identified in human tumours, including colon 
cancer. The k-ras gene is the most commonly mutated RAS family member in colon cancer, 
although N-RAS mutations are also observed in a small percentage of colon cancers [50]. 
The RAS family genes encode a highly conserved family of 21-kDa proteins involved in 
signal transduction. Ras serves as a GDP/GTP related binary switch with a crucial role in 
the transmission of growth regulating signals within the organism, and may be used as a 
critical terminal through which signals are passed on to other signalling modules (see Figure 
5). The best characterized of the signalling pathways regulated by Ras is the mitogen-
activated protein kinase (MAPK) pathway. This pathway is activated when Ras activates a 
Serine/theronine Phosporylation Cascade (Raf). Raf thereafter phosphorylates and activates 
a mitogen extracellular signal–regulated kinase (MEK), which phospyrates a mitogen-
activated protein kinase (MAPK). This in turn activates an extracellular signal–regulated 
kinase (ERK) that plays pivotal roles in a wide variety of developmental cellular processes, 
including growth, division, and differentiation [51].
The mutated k-ras product maintains a prolonged state of activation leading to cellular 
proliferation. Novel activating mutations in sporadic CRC have recently been identified on 
major kinase encoding genes such as BRAF [52] and PIK3CA [53]. The presence of these 
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activating point mutations, including the well-characterized k-ras oncogene mutations, is 
represented in up to 75% of cases of CRC. These genes, which have been implicated in the 
adenoma-carcinoma transition, cause deregulation and constitutive activation of the MAP 
AKT/kinase pathways, rendering growth advantages to colon tumour cells [54;55]. Mutated 
k-ras may also inhibit the TP53-BAX signalling pathway by phosporylating pro-caspase-9, 
and thereby inhibiting cythochrome c induced apoptosis [19;51].
The TP53-Bax pathway 
The TP53-Bax pathway is important in DNA damage, cell survival and proliferation. TP53
gene codes for a protein that acts as a transcription factor and serves as a key regulator of 
the cell cycle, coupling stimuli that promote cell division to those that promote cell death 
[57]. Mutations in the TP53 tumour suppressor gene are found at high frequency in a wide 
range of human cancers [58]. TP53 is also in control of Bax, which is a pro-apoptopic 
member of the BLC-2 family. It reduces cytochrome c released from mitochondria resulting 
in apoptosis (see Figure 6).
Figure 5. Modified after Juliano et al. [56]. 
The Integrin receptor activates the receptor 
tyrosin kinase. Secondly, Integrin enhances the 
efficiency of the cytoplasmic cascade 
comprising Raf, MEK and Erk. This activates 
adaptor proteins such as Grb2, which in turn 
can recruit other proteins such as SOS, a 
partner of Grb2. Grb2 is an exchange factor for 
Ras GTPase. Activation of Ras at the 
membrane by SOS leads to the recruitment of 
Raf. Raf is the first kinase in the 
intracytoplasmic signalling pathway leading to 
Erk. Raf subsequently phosphorylates and 
activates MEKK (MAP kinase kinase /Erk 
kinase) leading to activating of MEK (MAP 
kinase kinase) and MAPK (Map kinase), which 
leads to the activation of Erks. Activated Erk 
migrates to the nucleus, where it can 
phosphorylate its targets, leading eventually to 
cell replication.
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Folate metabolism 
Folate is a water-soluble B vitamin. The primary function of folate is as a coenzyme in 
reactions that require transfer of a single carbon moiety in different oxidative states as a 
methenyl, methylene, or methyl group. These reactions typically involve synthesis of 
compounds such as thymidine, a pyrimidine base necessary for synthesis of DNA. 
Consequently, folate status could potentially be perturbed by polymorphisms in genes 
important in the folate metabolism (see Figure 7). Folate deficiency could also affect 
malignancy by causing DNA hypomethylation and proto-oncogenic activation by inducing 
uracil misincorporation during DNA synthesis, leading to catastrophic DNA repair, DNA 
strand breakage and to chromosome damage [49;59]. A deficiency in folate plays an 
important role in the pathogenesis of anemia [60], atherosclerotic cardiovascular diseases 
[61], neural tube defects [62] neuropsychiatric and cognitive disorders [63] and cancer 
[64;65]. Colon cells are subject to rapid turnover, and thus are the site of high rates of DNA 
synthesis. Several studies have shown a link between low folate status and indicators for 
DNA damage [59;66], and that dietary folate intake could reduce the risk of colon cancer 
[67;68].
In cancer treatment it is well known that there are inter individual differences in tumour 
response and normal tissue toxicity [69-72]. Many clinical variables with inter individual 
differences have been associated with e.g. age, gender, diet and drug-drug interactions. 
Figure 6 TP53-Bax pathway. 
P53 transcritionally activates Bax, 
and integral membrane proteins 
Fas/APO1 and Killer/DR5. These 
integral membrane proteins are 
death receptors and activation of 
these results in activation of the 
caspase cascade. Cythocrome C 
released by Bax also activates the 
caspase cascade, which in turn 
activates endonuclease and 
thereafter DNA cleavage.  
This Figure was modified from 
[57].
20
However the major clinical variable is the DNA variation in genes of different populations. 
Genes that code for metabolism enzymes, receptor proteins or protein targets of 
chemotherapy agents often present different polymorphisms that can influence drug 
sensitivity and optimal dosing.  
Ataxia telangiectasia and the ATM gene
Appropriate cellular signalling responses to DNA damage and the ability to repair DNA are 
fundamental processes required for an organism’s survival. Ataxia telangiectasia (AT) is a 
rare neurodegenerative disease that results from defective DNA damage signalling [73]. 
This disease is characterized by neurological and immunological symptoms, sensitivity to 
radiation, and cancer predisposition. AT patients have a higher incidence of breast cancer 
and leukaemia than the general population and about one-third of patients develop a clinical 
significant malignancy during their lifetime [74]. The incidence of AT heterozygous 
individuals in the general population is estimated to be 0.5–1% [75-77]. Understanding the 
molecular basis of AT has provided many critical insights into the cellular response to DNA 
Figure 7 Highlights of the folate metabolism, including key enzymes involved and major regulatory 
mechanisms. Key enzymes are denoted as black boxes, substrates as white boxes. B2, B6 and B12 are vitamins.  
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double-strand breaks (DSBs). DSBs are the major DNA lesion leading to chromosomal 
aberrations and reliable repair is crucial for maintaining genomic stability. The gene 
mutated in AT, the ATM gene, has a role as DSB detector. The ATM gene encodes a protein 
kinase that is mainly distributed in the nucleus of proliferating cells. It appears to play a 
central role in cell cycle regulation, DNA repair and apoptosis and control of cellular 
responses to DNA damage [78].  The ATM gene has been fully elucidated [79] and the 
complete genetic sequence is known [80]. However, it’s large size (146 kb) and complex 
62-exon structure has greatly complicated the process of screening large sample sets for all 
possible sequence variations. DNA variations in the ATM gene have been studied in 
colorectal cancer [81-83]. These studies showed that expression of ATM could predict 
survival in colorectal cancer, and increase radio sensitivity. 
Methods to detect DNA variants 
One of the major trends in post-genomic research is the exploration of genetic variation in 
humans. The variation of a single base may lead to change in cellular behaviour, and this 
change could serve as a diagnostic marker or a target for future therapeutic intervention 
[84]. The completion of the Human Genome Project in 2003, and sequencing of the entire 
genome in more than one individual, made it clear that there are major individual 
differences in the genome, especially between different ethnic populations. Worldwide 
efforts to collect DNA variations have lead to several public databases. Validation of DNA 
variations and estimation of their allele frequencies are useful, because these markers can be 
used in genetic studies [85]. A high-throughput capacity is crucial to complete the large 
studies necessary for reports of such genetic studies.
Denaturant gradient gel electrophoresis and related techniques 
Many techniques are now available for discovery and scoring of DNA variations. One group 
of methods, the melting gel techniques have proven to be amenable and powerful tools for 
analysing DNA variations. The reason for melting gel techniques popularity rests upon the 
well-documented theoretical foundation of these methods, and the few laboratory steps that 
are needed in the analysis in combination with high specificity and sensitivity. Denaturant 
Gradient Gel Electrophoresis (DGGE) has been the most frequently used melting gel 
electrophoresis technique and was first described by Fischer and Lerman [86]. DGGE 
detects mutations (small deletions and insertions, point mutations) by separating PCR 
22
amplified DNA fragments, which differ from wild-type DNA in their melting behaviour, on 
a denaturing gradient gel. Fragments analyzed by DGGE must have appropriate melting 
characteristics, namely a low temperature melting domain and a single contiguous high 
temperature melting domain. A melting domain is defined as a region of DNA that melts 
cooperatively at approximately the same temperature or concentration of denaturant. The 
melting characteristics of a fragment can be predicted from its primary sequence, and 
computer algorithms are available to perform this analysis [87]. To include a larger part of 
the genome (those without a natural high temperature domains) applicable to this method 
Myers et al. [88] has reported that a GC rich 40-basepair region attached to one of the 
primers during initial PCR amplification increases the number of fragments that can be 
analysed with melting gel techniques. Thus constructing a high melting domain adjacent to 
the target sequence of the fragment. However there are some fragments with a single base 
alteration where no thermodynamic difference between the wild-type homoduplex and 
mutant homoduplex is achieved, even though a GC- rich content is attached [89]. These 
fragments will not separate the homoduplexes. However heteroduplexes in the low 
temperature domain of a fragment will resolve from the corresponding homoduplexes, so 
that the mutation fraction can be seen. To determine the nature of the variant DNA 
sequence, the heteroduplex peak can be collected and subsequently sequenced [90;91]. 
DGGE employs a linear gradient of denaturant in a polyacrylamide gel. Double-stranded 
DNA molecules migrate into the gradient in the gel until the point where a discrete 
denaturing concentration is reached. This results in a partially melted, Y-shaped molecule 
where mobility through the gel will decrease drastically. The separated amplification 
products can be made visible on an UV-transilluminator after incubating the gel with an 
ethidium bromide solution, cyber green or other DNA intercalating dyes. Separation in the 
gel can be seen in Figure 8A. In this figure we can observe 4 bands. During the PCR 
amplification of a fragment containing a point mutation four different variations of the 
amplification product will be produced. Two homoduplexes, representing the wild-type 
fragment and the mutant fragment with perfectly matched sequence. Secondly, two 
heteroduplexes, representing imperfectly match of forward wildtype and reverse mutant 
sequence or forward mutant fragment and reverse wildtype.  
There have been modifications in melting gel techniques. Temporal Temperature Gel 
Electrophoresis (TTGE) [92;93] is applicable without the requirement of using a chemical 
denaturering gradient. The temperature is increased gradually, that result in a linear 
temperature gradient over the timecourse of the electrophoretic run. Temperature Gradient 
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Gel Electrophoresis (TGGE) [94] provides a temperature gradient instead of a chemical 
gradient.
Constant Denaturant Gel Electrophoresis (CDGE) [95] is another modification where the 
method has the advantage of enabling the fragments to migrate at a consistently different rate
through the whole gel. This allows greater separation between mutant and wild-type 
fragments [95-97]. 
Modification of the CDGE to the capillary platform was first published by Khrapko in 1994 
[98;99] (see Figure 8B). The application of Constant Denaturant Capillary Electrophoresis 
(CDCE) was first developed on a laboratory-assembled instrument [100]. Benefits of 
capillary-based electrophoresis (CE) include fast sample runs and data storage capability 
and increased limit of detection; in addition, only minimal amounts of sample are required 
with CE techniques. Elevating the temperature of a section of the capillary change the 
denaturing conditions for CDCE. Various methods have been used to apply temperature 
gradients to capillaries including the use of a voltage ramp [98], an external heating plate 
[101], Peltier-based control of surrounding liquid [102] and heated air [103]. A further 
improvement of CDCE allowing two-point detection and automated fraction collection has 
been reported [104;105]. Conversion of CDCE into regular commercial capillary DNA 
sequencing instruments has resulted in automated and standardized protocols [106]. 
Virtually any commercial single or multi capillary instrument may be used. The automation 
allows for rapid analysis of a large number of samples for a short period of time, with no 
interference by the operator. The method was first described with the use of an ABI 310 
Genetic Analyzer, in which up to 48 samples could be analysed without need of the operator 
[107]. This method has also been adapted to the Megabace¥1000, allowing for analysis of 
96 samples within 40 minutes [108;109], ABI 3100 genetic analyzer [110], a SCE2410 24-
capillary instrument from Spextrumedix [103;105], Beckman Coulter eight capillary 
(unpublished data) and tested on MegaBACE 4000 with 384 capillaries (unpublished data). 
The temperature control for the method has been improved by modifying the CE system 
with the use of a temperature gradient [109].
Samples are analyzed with a temperature gradient starting above and declining beneath the 
optimal separation temperature, controlled by the computer software. This modification 
compensates for the temperature differences in the capillary chamber resulting in a robust 
method. Additional improvement of the gradient is accomplished by cycling the gradient 
several times around the optimal separation temperature [111;112].  
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Application of Denaturant capillary Electrophoresis (DCE) 
Mutation analysis 
It is widely accepted that human cancer is a genetic disorder caused by sequential 
accumulation of mutations in oncogenes and tumour suppressor genes. These tumour-
specific mutations in cellular processes underlying tumorigenesis have proven to be useful 
for diagnostic and therapeutic purposes. In the past, the selection of genes chosen for 
mutational analyses in cancer has been guided by information of known functional attributes 
of individual genes or gene families. With the determination of the human genome sequence 
it is now in principle possible to examine the cancer cell genome in a comprehensive and 
unbiased manner. Such an approach not only provides the means to discover other genes that 
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Figure 8. This figure shows the 
adaption of DGGE (A) to 
Denaturant Capillary 
Electrophoresis (DCE) (B), where 
the picture of a gel with 4 bands 
(nr 4 and 3 heteroduplexes 2; 
mutant and 1; wild type) 
corresponds to the 
electropherogram obtained by 
DCE.
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contribute to tumorigenesis, but can also lead to mechanistic insights that are only evident 
through a systems biological perspective. One consideration of mutation detection analysis 
is the possibility of detecting mutations in a small fraction of samples. To study rare variants 
in the human population or new somatic or germline mutations, a technique is required 
which can detect and separate any and all of the variety of mutations in a target gene at 
fractions from the wild-type DNA. This can be important for early detection of malignant 
diseases, detection of remaining cells after surgery and possibly for prognosis and outcome 
of the disease. Several different mutation analyses have been performed by DCE 
[90;92;100;104;105;113-119]. A major improvement to the method was conversion to 
commercially automated capillary instruments. The first report was on a single capillary 
instrument; the ABI 310 Genetic Analyzer, where mutations of k-ras exon 1 [120] and exon 
5-8 in TP53 gene were analyzed [107]. The same mutation analyses have also been 
performed on the commercial MegaBACE¥1000 instrument, [108;109;111;121;122], and a 
SCE2410 from Spextrumedix [103;105]. 
Single Nucleotide Polymorphism (SNP)  
Single nucleotide polymorphisms or SNPs are DNA sequence variations that occur when a 
single nucleotide (A, T, C or G) in the genome sequence is altered. For a variation to be 
considered a SNP, it must occur in at least 1% of the population. SNPs, which make up 
about 90% of all human genetic variation, occur on average once every 87 bp along the 3-
billion-base human genome. 8 354 954 SNPs are currently registrated in the CHIP 
Bioinformatic tool database [123;124], however only 60 % are validated, 11% of these 
SNPs have frequency data and 40 % of the SNPs are located in genes. Two of every three 
SNPs involve the replacement of cytosine (C) with thymine (T). SNPs can occur in both 
coding and noncoding regions of the genome. Although more than 99% of the human DNA 
sequence is identical in all human beings, variations in DNA sequence can have a major 
impact on how humans respond to disease, drugs and other therapies. This makes SNPs of 
great value in biomedical research and in developing pharmaceutical products or medical 
diagnostics. SNPs are also evolutionarily stable. This makes SNPs a popular tool to 
discriminate between alleles or haplotypes in population studies. The DCE method has 
proven to be a robust method for genotyping alleles and also detection of new SNPs. Target 
sequences require only PCR amplification followed by allele separation by capillary 
electrophoresis. The genotypes of the individuals SNPs are scored based on co-migration to 
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an internal standard. Due to the presence of an internal standard in all the electrophoretic 
runs, the specificity of the SNP analysis is increased as allelic separation of the standard is 
required before genotypes can be determined [89;125] (see Figure 9). Discovery of new 
unpublished SNPs in the target fragment are also possible with this method. Detection of 
unpublished SNPs will be discovered by aberrant peak pattern compared to the internal 
standard, and may be verified by DNA sequencing. In a study by Lorentzen et al. [126] six 
microsatelittes and three SNPs in two Norwegian populations were analysed by three 
different methods; PCR-RFLP, TaqMan£ analysis and DCE. The genotype error rates when 
comparing PCR-RFLP with TaqMan£ data or the DCE were notably higher than 
comparison of genotype error rate for TaqMan£ and DCE. These analyses showed that both 
DCE and TaqMan£ were superior to the PCR-RFLP method when it comes to accurate 
genotyping of the selected SNPs. 
Microhaplotypes 
Microhaplotypes are in general defined as the presence of several SNPs within a short DNA 
fragment (100-1000bp) [127]. The theoretical number of possible alleles is defined as 2n,
where n is the number of SNPs in the sequence analyzed. Possible combinations of 
genotypes are given by the sum of numbers from zero up to numbers of alleles. Few 
methods are able to analyze microhaplotypes, and the protocols are in general labour 
intensive and not easily automated [127;128]. Consequently, DCE has been optimized for 
microhaplotyping by use of the standard method. This method has been used to identify 
three SNPs within the ATM gene based on theoretical thermodynamics and migration of 
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Figure 9 shows a SNP in MTHFR 
NCBI (rs 1801131) with three genotypes 
(thin) co-eluted with an internal standard 
(thick). Heteroduplexes are not shown.  
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various fragments [125]. Another study has also used this method to detect 3 
microhaplotypes in the CTLA4 gene [126]. A review by Szantai et al. [129] summarizes the 
recent examples of novel and emerging haplotype techniques by capillary electrophoresis 
based on DNA fragment analysis, with DCE as one of the methods mentioned.
Gene copy number 
Pooling designs are used in screening experiments in molecular biology. In some 
applications, the property to be screened is defined on subsets of items, instead of on 
individual items. Pooled genotyping is a powerful and efficient tool for high throughput 
association analysis, both case-control and family based [130]. The use of a pooling design 
may reduce the consumables and labour cost of a study compared with genotyping 
individuals and counting alleles. Pooling allows a far smaller number of PCR reactions and 
genotype assays than are used when genotyping individuals. The most important 
consideration with DNA pooling is to ensure that the individuals that make up a pool 
contribute equal amounts of DNA, from which robust PCR results can be obtained. 
However random experimental errors in the constitution of DNA pools and in the 
measurement of allele frequencies from pooled DNA should be taken into account in 
statistical analysis [131]. Differential amplification occurs for many SNPs and this bias 
should also be corrected for in the estimate of allele frequencies from pooled DNA. Several 
reports have stated that multiple genotyping techniques are suitable for pooled genotyping 
[132;133]. Pooled DNA has been used in studies of various diseases, such as head and neck 
carcinogenesis [134], breast cancer [135], Liddle syndrome [136] and rheumatoid arthritis 
[137]. The DCE method has also been shown to be an effective and cost- beneficial method 
for single and pooled samples [110;119;138]. There is no need for any correction of the 
signal of the separated alleles because both alleles are separated with the same flourophore 
and because fragments of the same length with a difference of one base pair will pass the 
detector with the same velocity [90]. By measuring the area under the peaks (alleles), 
quantitative information about DNA copies entering the PCR reaction are obtained. Harbo 
et al. [139] have recently published a study where four sets of 1000 blood donors were 
pooled and analyzed for 41 SNPs involved in T cell signalling. The authors also concluded 
that screening of SNPs in DNA pools proved to be efficient and cost-effective, because 
many of the reported non-synonymous, polymorphic SNPs were in fact not polymorphic in 
the large Norwegian cohort. Morgenthaler and Thilly [140] have recently described a
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strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases 
with a cohort allelic statistical sums test called CAST. The techniqual approach in this paper 
is the DCE method. Based on genetics, technology and statistics, case cohort samples of 
10,000 persons for each of 100 common diseases are proposed and evaluated.  
Allelic imbalance 
Most human cancers show genetic instabilities leading to allelic imbalances. Allelic 
imbalance may be described by means of the two-hit model by Knudson in which one allele 
is mutated and the other allele is lost through a number of possible mechanisms, resulting in 
the loss of heterozygosity (LOH) at multiple loci [141]. Allelic imbalance has been detected 
by allotyping using restriction fragment length or microsatelitte markers [142]. To 
determine this allelic imbalance (allelic loss/reduction or gain) in tumour samples, 
microsatelitte markers at gene loci of interest have been used. A disadvantage of using 
microsatelittes is that they are rare compared to SNPs and generally located in non-coding 
regions of the genome. To circumvent the use of microsatelittes we can apply regular SNP 
analysis by DCE as means for determining allelic imbalance (see Figure 10).  
Thermodynamics of double stranded DNA 
In 1974 Poland proposed an algorithm able to calculate the melting probability of thousands 
of nucleotides in dsDNA [143]. Based on nearest neighbour correlation in specific sequence 
macromolecules and basic principles of DNA thermodynamics, the algorithm stated that 
dsDNA melts to single stranded DNA (ssDNA) when exposed to sufficiently high 
temperatures and/or chemical denaturants (i.e., formamide and urea). Specifically, the 
length of the DNA fragment and the nucleotide sequence within the fragment defines the 
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Figure 10. Allelic imbalance 
analyzed by DCE. Ratio of the two 
alleles in the upper sample is 1:1 as 
expected for a heterozygous sample. 
In the lower electropherogram a clear 
imbalance between alleles can be 
seen.
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melting temperature at which each bp of a DNA duplex is in perfect equilibrium between 
the denatured and helical state [86]. Because GC pairs consist of three hydrogen bonds, 
while AT pairs only have two, the temperature at which a particular DNA molecule 
denaturates usually will increase with higher percentage of GC pairs. Importantly, DNA 
variants differing by only one base will reveal different melting profiles based on the 
sequence variation (see Figure 11). 
Other scientists have subsequently proposed approximations and modifications of Poland’s 
algorithm [87]. The need for approximations relied on the fact that an exact algorithm 
required computer time proportional to N2, were N is number of bp in the target dsDNA. 
Computer software programs such as SQHTX (Lerman and Silverstein), Melt87 [87], 
WinMelt (Medprobe, Oslo, Norway) and the Poland internet web site [144] are important 
tools to mimic the Tm melt-curves. 
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Figure 11. Thermodynamics of the DNA sequence from the gene MTHFR (NCBI rs 2274976) with use 
of Poland’s algorithm [87]. 
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Sensitivity  
The quantitative sensitivity is here defined as the detection limit i.e. the lowest level an 
aberrant fragment sequence can be detected in a background of wild-type fragment. On the 
capillary platform this limit is reported to be 1% for the homoduplexes and 0.1% for the 
heteroduplexes for a range of target sequences [104;109;145]. Furthermore by utilizing the 
DCE method in combination with enrichment of mutants by fraction collection and high 
fidelity PCR, mutant alleles in a ratio equal to or greater than 2 x 10-6   have been detected 
[146].
Specificity
The specificity of melting gel techniques is defined as the ability to detect a wild type 
sample as neither mutant nor aberrant. If a PCR is not optimal it can make artefact PCR 
products, for example primer dimers or pseudogenes, which may form bands and peaks that 
lower the specificity of the test. To increase the specificity several approaches can be taken. 
The analysed sample with the corresponding homo and heteroduplexes can be reanalysed at 
slightly different denaturing conditions. In the reanalysis target sequences will migrate 
relative to each other due to altered denaturing conditions. Peaks that represent artifact 
products will not. 
Figure 12. A sample SNP analyzed with DCE 
at three different cycling temperature conditions: 
The peaks in the electropherograms numbered 
from 1 to 4, represent the peaks of the sample. 
Peak X represents an artifact PCR product. When 
the temperature is increased, the average velocity 
of the homo and hetero duplexes is reduced, thus 
the amplified DNA will elute later. The artifact 
peak does not migrate with a different velocity 
when the temperature is changed. It either
represents a dsDNA molecule with a different 
sequence or ssDNA. With permission from [147].
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Another way to identify a “false positive” is to use a DCE unit with two detection points on 
the same capillary. This permits the precise calculation of the fragment velocity after 
separation in the heated zone because at room temperature all DNA fragments of the same 
length have the same velocity. Also the two-point detection system allows rapid distinction 
between double-stranded and single-stranded DNA fragments of the same length [90]. High 
reproducibility is important and allows direct identification of known DNA variants based 
on relative migration to an internal standard [89;125] see Figure 13. Notice that the 
electropherograms are not corrected for differences in running conditions due to temperature 
differences in the different capillaries. 
Figure 13. This figure demonstrates 
genotype identification of a SNP in MTHFR by 
co-elution with an internal standard (thick line), 
samples (thin line) were scored as TT, GG and 
GT respectively. Heteroduplexes are not 
shown. The figure shows representative 
electropherograms from different arrays within 
the MegaBACE instrument. The 
electropherograms are not corrected for 
differences in running conditions. The analysis 
time for 96 samples was approximately 34 min. 
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Methodological considerations 
Several methodical considerations have to be taken into account before adopting this 
method into the lab. First of all it is important to choose genetic markers in the study design. 
A selection of markers is often based on previous observation of gene mutations/alterations 
in human cancers. Another consideration is proper primer design. When the DNA sequence 
of the template is known it should be possible to select target specific primers based on 
standard primers selection criteria’s [148]. Computer programs such as Primer 3 [149] can 
be used to assist primer design. There is also important to make sure that primers do not 
anneal to pseudogenes in the template. Pseudogene is a sequence of DNA that is very 
similar to the normal gene but has been altered slightly so that it is not expressed. A nested
PCR protocol can circumvent amplification of a pseudogene.
When designing primers it is also important to be aware of duplicate gene nomenclature 
given to the same gene product, distinct names given to splice variants of the same gene and 
alterations of number of exons and introns in a gene. Furthermore it is important to evaluate 
the target sequence with the allele differences with regard to the melting properties of the 
DNA prior to any laboratory intervention. The simulation of the melting properties by a 
computer program gives information if the fragments can be analysed by the DCE method. 
All target sequences in this thesis were analyzed with the WinMelt (Medprobe, Oslo, 
Norway) computer program, which revealed the theoretical melting profiles of the 
fragments.  
Once the primers are made the main attention is to make a reliable PCR product. The PCR 
product is the key to this capillary method. Optimising the chemical conditions and PCR 
programs for the target fragments is important. One challenge is the PCR specificity and the 
accumulation of non-specific PCR products. We have observed labelled ss DNA as an 
artifact peak, which can migrate similarly to the mutant peak and the heteroduplexs peaks, 
and confuse the scoring of the alleles. Adding more of the unlabelled primer making an 
unbalance in favour of the unmarked primer can solve this problem, because the amplifying 
of this unlabelled ss DNA will not be visualized in the analysis. Another requirement is to 
make a fragment specific internal standard for the genotyping of the analyzed fragments. 
The internal standard is made from a heterozygous sample from the target sequence, by 
reamplifying a diluted sample with a different fluorophore attached to a 20mer primer with 
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the same sequence as the 20 last base pair of the GC-clamp. Verification of the alleles in the 
internal standards is done by DNA sequencing. 
In this thesis we analysed tumour from rectal cancer patients. Solid tumour samples in 
cancer research are invaluable, as they directly reflect the in vivo situation. However, as 
soon as the tumour is removed from the body, the tumour environment is exposed to 
possible degradation of the sample. For that reason the surgeons placed the tissue sample 
directly in a tube with RNAlater®. RNAlater® (Ambion, United Kingdom) is an aqueous, 
nontoxic, tissue storage reagent that rapidly permits most tissues to stabilize and protect 
DNA and the more unstable RNA in fresh specimens. 
Several considerations regarding the pelvic lavage fluid that has to be taken into account 
before interpreting the data from the analysis. The first is the viability of the disseminated 
cells in the lavage fluid. We concede that there are no causal connection between mutant 
positive DNA and viable cells in the lavage. However, at the present there are dew methods, 
to reliably test the viability of the tumour cells. Secondly, the surgical procedure involves a 
washing step with sterile water that may compromise an unknown amount of the free 
floating cells. However, it has previously been demonstrated that complete cell lysis with 
sterile water requires considerably longer period of incubation than is currently practiced 
[150].
Another important consideration is to secure that the detection limit for the mutation 
fraction is good enough, especially for the lavage fluid. Minor or moderate bleeding in the 
surgical area results in more white blood cells in the lavage samples, which can make 
mutant fraction below the detection limit. This could have been the problem in the second of 
the two samples because the haemostasis was not complete when lavage was carried out. It 
was therefore important in the first study in this thesis to prove that the detection limit was 
sufficient in automated standards sequencing instruments.  
For many diseases such as rectal cancer, population-based studies of unrelated individuals 
such as case-control and cohort studies serve as standard designs for genetic association 
analysis and can be the most practical and powerful approach. However, extensive debate 
has arisen about optimum study design, and concern has been expressed about the 
population stratification of such approaches, which can lead to biased or false results. 
Unfortunately, allele frequencies are known to vary widely within and between populations, 
irrespective of disease status. This difference in frequencies arises because each population 
has a unique genetic and social history. These differences are widespread throughout the 
genome including many genes of known medical relevance. In effect, nearly all populations 
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are confounded by genetic admixture at some level. The challenge is not only to show that it 
exists, but also to avoid making incorrect conclusions because of it.  
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Aims of this project 
1. To adapt DCE methods for use with commercially available single-and multi-capillary 
instruments. 
2. To collect tissue and lavage fluid from rectal cancer patients operated at the Norwegian 
Radium Hospital. The samples were prospectively registrated and anonymized before being 
stored.
3. To apply the DCE method to detect selected DNA variations important in the adenoma-
carcinoma sequence and in pharmacogenomic aspects of rectal cancer patients. 
4. To study the possibility of using the developed DCE method with a marker for the k-ras
gene to verify free tumour cells in the abdomen after surgery in rectal cancer patients. 
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Results in brief
Paper I 
In this paper we analysed PCR products from TP53 with temperature gradient 96-array 
capillary electrophoresis to evaluate the sensitivity, robustness, and throughput of the 
method. By gradually decreasing the temperature in combination with a chemical denaturant 
in the gel, separation between homoduplexes and heteroduplexes in mutated TP53 exon 8 
was achieved. PCR products from a mutated sample were analysed in all 96 capillaries 
simultaneously. A sensitivity experiment was done, where mutants and wild-type PCR 
products were mixed in various ratios. The results showed a loss of heteroduplex signal 
below mutant fraction of 4 x 10-3. Another feature of this study was to show the robustness 
of this method with respect to the separation of different mutations occurring in exon 8 of 
the TP53 gene. The mutations displayed are sited within 48 bp of the conservative region of 
the gene. 
Paper II 
The aim of this study was to demonstrate the use of automated constant denaturant capillary 
electrophoresis (ACDCE) of various target sequences on an ABI 310. First the target 
sequences were theoretically evaluated to see if they were suitable for the melting gel 
analysis. Primers were ordered, PCR optimised and analysed with ACDCE. To determine 
the best separating conditions, samples were reanalysed with increasing temperatures based 
on the theoretical thermodynamics of the fragments. It was possible to adjust the 
temperature so that the separation was achieved between both alleles for all amplified 
fragments. For direct identification of SNPs, an internal standard with a known genotype 
was added to each tube prior to ACDCE, and the sample was compared to the peak pattern 
of the internal standard. 
Paper III 
In this paper three polymorphisms in the ATM gene IVS38-8T/C, 5557 G/A and 5558 A/T 
were analysed in 3526 samples from different blood donors and 151 sporadic rectal cancer 
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patients by the method CTCE. The different alleles were resolved by melting of double 
strand DNA. Partial melting of DNA fragments were detected as changes in mobility during 
electrophoresis. All samples were run with an internal standard. Knowledge of melting 
behaviour for different microhaplotypes relative to the wild type combination combined 
with DNA sequencing allowed direct determination of microhaplotypes, and more than 
7000 alleles were analysed this way. The ATM polymorphisms and microhaplotypes 
examined did not significantly differ between sporadic rectal cancer patients and the normal 
population.
Paper IV 
In this study 333 patients diagnosed with rectal cancer and a control population of 384
anonymous blood donors were genotyped for nine SNPs in five different genes involved in 
folate metabolism. SNPs in MTHFR c.1793C>A, MTHFR c.1298A>C, MTHFR c.677C>T, 
MTRR c.66A>G, CBS c.699C>T, SHMT c.1420C>T, DPYD c.85G>A, DPYD c.1896G>A 
and DPYD IVS14+1 G>A where genotyped by cycling temperature capillary 
electrophoresis (CTCE). SNPs in the MTHFR gene (c.1298A>C and c.677C>T) and DPYD 
c.1896 A>G showed evidence of being associated with rectal cancer with p value of 0.02, 
0.03 and 0.01, respectively. However by applying the stringent multiple testing corrections 
(Bonferroni adjustment), these p values were not considered significant in a multiple testing 
settings.
Paper V 
In this pilot study we found the frequency of k-ras mutations in rectal tumours to be 30% in 
the Norwegian rectal cancer population and one-third of these showed k-ras mutations in the 
lavage fluid. Of the eleven possible risk factors tested with regard to patients with positive 
and negative k-ras markers in the lavage fluid only N- and R-stage were significantly 
different between the two groups (p=0.03 and p= 0.002, respectively). This was mainly due 
to a higher percentage of N0 and R0 stages in the k-ras negative group. Our results showed 
that 12 of the 19 positive K-ras were R0, which was an unpredicted result. Of the 19 patients 
that had a positive k-ras in the lavage fluid taken at the end of the surgical procedure, 13 had 
a primary tumour and 6 had a recurrent tumour. For the patients negative for k-ras
mutations 178 had a primary tumour and 42 had a recurrent tumour. Survival rate was 
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estimated by Kaplan-meier’s plot and a log rank test. The observation time was a median of 
22 months. Results showed that patients positive for the lavage marker has a mean survival 
of 22 months compared to 46 months for where negative (p=0.006) patients. As a result, 
differentiation between patients with or without free tumour cells in the peritoneal cavity 
could indicate that an additional local or general treatment of patients with k-ras mutant 
positive lavage was necessary, independent of the R stage or other pathological features, 
which are the usual indicators of such treatment. This should be further studied in a large 
multicenter study and if possible with more mutation markers to cover a wider number of 
malignant tumors.
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Discussion
CRC provides a good model both for the study of disease susceptibility and for the somatic 
evolution of epithelial cancer, due to the fact that CRC of all stages are more readily 
accessible than most other carcinomas. Furthermore, many of the genetic and molecular 
alterations, which lead to CRC, have been identified. However, both clinical and laboratory 
factors need to be considered when evaluating molecular tools of prognosis and prediction.
Biological considerations 
In this thesis there have been two study populations. The case population were the rectal 
cancer patients (paper I, III, IV and V) and the control population were blood donors at the 
Blood Bank, Ullevål University Hospital (paper II, III and IV).   
Tumour biopsies were taken with a chonchotome through a proctoscope before or in a few 
cases after irradiation. In some patients a tumour sample was taken from the operative 
specimen. One important consideration is to secure that the tissues really are tumour and not 
normal surrounding tissue. Most tumours show genetic instability with loss of 50/50 
heterozygous distribution. Hence detection of such allelic imbalance is a good indication 
that a sample DNA is derived from tumour cells. In this thesis randomly selected tissue 
samples were subjected to analysis of allelic imbalance to validate that the sample contained 
tumour cells (data not shown).  
We analysed rectal cancers, which have been proven in many aspects to be different from 
colon cancers. This may explain some conflicting results in paper III-V compared to other 
studies. It is well known that clinical behaviour is different between colon and rectal cancer, 
and it is therefore reasonable to suggest that the cause factors and the molecular basis may 
also differ. The colon cancer carcinomas that arise proximal (right) or distal (left) have 
differences related to epidemiological, clinicopathological, biochemical as well as genetic 
factors. Rectal carcinomas are assumed to arise through similar mechanisms as distal colon 
tumours (descending and sigmoid colon). Other scientists [151] recommend not to 
subdivide patients into colon and rectal cancer, but to see them as a homogenous 
component. This may explain some of the different results obtained in our study compared 
to others using a mixture of colon and rectal cancers.  Another consideration in this thesis is 
that The Norwegian Radium Hospital is a third line cancer center with a high-volume of 
locally advanced or locally recurrent surgical rectal cancers (TNM stage II and higher). 
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Many markers are associated with rectal cancer, and in paper III we speculated that  
ATM could be a candidate for a modifier gene. The ATM gene was investigated, due to a 
target sequence with three polymorphisms (IVS 38-8 T/C in intron 38, 5557 G/A and 5558 
A/T in exon 39) to demonstrate the ability of the method to detect 3 different 
polymorphisms in a short target sequence. This resulted in eight possible microhaplotypes at 
the DNA level. Furthermore, the two exonic SNPs are sited next to each other, allowing 
four possible amino acids in the same codon. No association was found between the 
polymorphisms and the haplotypes in the ATM gene with respect to the Norwegian sporadic 
rectal cancer patients. A number of studies have been performed to determine if there is an 
association between ATM mutations and cancer, but with conflicting results 
[81;82;152;153]. However, it is common that studies of allele frequencies vary in different 
populations. This can be explained by the fact that differences in population are influenced 
by the contribution of several genetic polymorphisms and by various environmental factors. 
In these cases any one of the genetic polymorphisms is neither necessary nor sufficient for 
the development of a given phenotype. Thus replication of association studies in different 
ethnic groups is of considerable importance, to better reveal the role of a given genetic 
polymorphism.  
Polymorphisms in genes involved in the metabolism of folate and methyl groups have been 
implicated with risk of colorectal cancer. In paper IV we compared differences in DNA 
variations in genes important in the folate metabolism between rectal cancer patients and the 
general population. Our results indicate that there is a trend towards an association of DNA 
variants in genes in the folate metabolic pathway and the Norwegian population of rectal 
cancer patients. Different studies of these DNA variations report conflicting results [154]. 
Theses variations may rest upon several different factors; variant specificities of different 
screening technologies used, the sample size of the studies and ethnical population 
differences.
In the association studies (paper III and IV) we have used anonymous blood donors from the 
Oslo blood bank as the normal population. Hence information on the age and gender 
distributions was unknown. However two studies have reported on the age of the donors by 
surveys of people donating blood to the Oslo blood bank in 1998 and 2000, the same years 
these samples were collected [155;156]. They concluded that the donors ranged from 19-70 
years (mean 40.5 years), and that donors were slightly overrepresented in the age 26-55. A
recent study of Hinselwood et al [110] on gender determination on the same anonymous 
blood samples agreed with the results presented in the surveys. Rectal cancer is 
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predominantly a disease of the elderly. At the time of diagnosis more than 40% of rectal 
cancer patients in Norway are older than 75 years [4]. The rectal patient population in this 
thesis had a mean age of 65 years. We then have to assume that most of the blood donors 
are in a different age group than the rectal patient group used in these studies, and some of 
the people in the control group may obtain rectal cancer in a later period of their life. 
Associations between genotype and outcome may be confused by unrecognized population 
stratification, in this study the stratification is age. However the 25 years of age difference in 
the two populations is not significant different due to probability of death at age [157]. For 
this reason we can assume that no significant amounts of alleles important in the disease of 
rectal cancer disappear between the age of 40 and 65. To control for hidden population 
stratification in genetic-association studies, we are aware of proposed statistical methods 
using marker genotype data to infer population [158-160]. However these methods are not 
used in this study. 
In paper IV we have corrected for multiple testing, by the Bonferroni method that allows 
many comparison statements to be made or confidence intervals to be constructed while still 
assuring that an overall confidence coefficient is maintained [161]. Results from different 
association studies may differ as a result of Bonferroni correction or the absence of it.
In paper V, we use k-ras as a tumour-associated marker to determine the presence of 
disseminated tumour cells in peritoneal lavage samples from patients undergoing surgery for 
rectal cancer. The protooncogene k-ras was chosen because this gene is frequently mutated 
in colorectal carcinoma [151;162] and located in a small hotspot region, which makes it 
possible to detect 80-90% of k-ras gene alterations with a simple PCR followed by DCE. 
Given the procedure and the sensitivity of the k-ras assay, minor or moderate bleeding in 
the surgical area could result in a mutant fraction below the detection limit. E.g. 1 microliter 
of blood contains on average 5000 white blood cells, hence if 10 millilitre of blood leaked 
into the lavage area some 50 000 k-ras positive tumour cells would be required for 
detection.  Despite this stringent limitation, k-ras mutant positive cells were detected in 
lavage fluids from the pelvic cavity. Mutated cells were found in the lavage fluid of 19 
patients, which had a significant correlation to the survival. Microscopically and 
macroscopically surgical margins are important indicators of recurrence and survival. 
However, our results showed that 12 of the 19 patients positive for k-ras mutations were R0 
stage, which was an unpredicted result. We would have expected R1 or R2 stage patients as 
the biggest contributors to disseminated cells in the peritoneal cavity. Cutting into the 
circumference of macroscopic (R2 resection) or microscopic tumour tissue (R1 resection) or 
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into the depth of the tumour can of course contribute to disseminated cells in the peritoneal 
cavity as well as by tumour infiltration of serosa or peritoneal carcinomatosis. As there were 
relatively more R0 stage resections in the k-ras negative group this should not explain our 
finding. However, in this case one of the R0 patients had serosa infiltration and one 
peritoneal carcinomatose. Lymph node metastases might contribute by a possible shedding 
of cancer cells when seveing an infiltrated lymphatic vessel. Therefore detection of 
exfoliated tumour cells may be a useful prognostic indicator based on these findings, 
independently of the R and N stage or other pathological features. Several other studies have 
performed detection of disseminated cells in the peritoneal cavity and prognostic value of 
these methods. Most of them have used cytological and immunohistochemistry methods. 
Low sensitivity and specificity might contribute to conflicting results using these methods in 
detection of disseminated tumour cells [163-165]. With the introduction of PCR, smaller 
quantities of DNA could be detected and the sensitivity and specificity be improved. The 
robustness of the analysis has been improved by fluorescence-based allelotyping techniques 
involving capillary electrophoresis [166;167].
In this pilot study we found the frequency of k-ras mutations in rectal cancer to be 30% and 
one-third of these showed k-ras mutations in the lavage fluid. One limiting factor of this 
study is that a marker is not present in about 70% of rectal cancer patients. Due to this other 
gene mutations need to be investigated to approximate 100% sensitivity. Pelvic lavage 
samples before and after tumour resection, tumour samples and blood samples from all the 
patients would also have contributed to increased sensitivity and a more robust study. We 
therefore underline that this study should merely act as a trigger for a larger multicenter 
study using a number of genetic markers. Due to the above-mentioned reasons sufficient 
number of cases allowing multiple regression analysis should allow a conclusion of 
importance of preoperative intraoperative contamination of tumour material. 
There are conflicting results when it comes to the prognostic significance of mutated k-ras
in the primary tumour. This is likely to arise from differences in study size, patient 
selection, tumour sampling, in use of archival versus fresh/frozen material, and in laboratory 
methods and data analyses. Mutant k-ras was in fact indicative of worse prognosis in CRC 
in some published studies [168-174], but not in others [164;175-178]. Differences among 
specific mutation classes were also observed independently in some studies 
[169;173;174;179].
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Instrumentation considerations 
In this thesis we have demonstrated and used an automated DCE method on a single (paper 
II), or a 96 capillary (paper I, III, IV, V) instrument. 
We used the theoretical melting temperature corrected for chemical denaturant as a 
guideline for an estimated run temperature and observed differences in temperature controls 
in the two instruments used in this thesis. The irregularity may be explained by differences 
in design and size of the capillary chamber. For the single capillary instrument the ABI 310, 
the temperature control was satisfactory. The 310 Analyzer utilizes a ceramic heat plate to 
control the temperature around parts of the capillary during the electrophoresis. 
For the MegaBACE 1000 irregularity in temperature was observed. This instrument has a 
rather large capillary chamber containing 6 arrays with 16 capillaries each. Within the 
chamber, the airflow can give up to 1.5°C differences in temperature between capillaries 
depending on the position in the chamber. To compensate for this temperature differences in 
the chamber, gradually decreasing temperature was used during electrophoresis in paper I. 
The temperature gradient makes the temperature control more robust, especially compared 
to CDCE where the temperature has to be strictly controlled to achieve separation [92]. This 
can be explained in that use of the gradient ensures that the capillary will pass through the 
optimal temperature for the target fragment. However, Bjørheim et al. [180] demonstrated 
later that neither constant temperature, nor temperature gradients allow optimal temperature 
distribution across all capillaries in a 96-capillary format. Consequently, temperature 
controls were improved by cycling the denaturing temperature around the theoretical 
transition state temperature. Cycling of the temperature during electrophoresis leads to 
almost equal conditions in all capillaries and between runs [112] (paper III, IV and V). 
Minarik et al. [122] have also used cycling temperature for the DCE method for mutation 
detection of several tumour suppressor genes. A total of 7 different somatic mutations were 
identified among 32 k-ras mutant samples, 1 inherited mutation and 5 somatic mutations 
were identified among 15 APC mutated samples. In paper II we used a commercial single 
capillary instrument. The temperature control in the ABI is not able to make a temperature 
gradient, and could only be adjusted with increments of 1°C. This may require more prerun 
optimizing before 48 samples could be analyzed without any intervention. We used POP-
4TM and POP-6TM in the setup to make all parts of the protocol commercially available. 
Migration time between homoduplexes was prolonged with POP-6TM as compared to POP-
4TM. This is most likely due to increased level of polyacrylamide in POP-6TM [181]. DCE is 
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a powerful tool for analysis of DNA variation. The development of a commercial multi-CE 
instrument allows large-scale studies of DNA variation. However, the cost of consumables 
like capillary arrays and sieving matrix might limit the use of DCE in such studies. Ekstrøm
and Bjørheim [182] has tested the ability of 72 different in-house formulated sieving 
matrices to separate PCR-amplified alleles by CTCE. They demonstrated that allelic 
separation is possible independently of matrix as long as the temperature, corrected for urea 
concentration in the polymer, is cycled in the vicinity of the Tm of the target sequence. The 
broad window of separation of alleles makes the method simple to apply to new fragments. 
This will make CTCE more accessible to the general research community (not only 
technology specialists), with the need only for theoretical estimation of melting 
temperatures as the basis for selection of cycling conditions. This is in contrast to screening 
methods like Single Strand Confirmation analysis (SSCP) and denaturant high performance 
liquid chromography (dHPLC). SSCP has no theoretical foundation to predict the separation 
condition, thus relying entirely upon empirical data for each fragment [183]. On the other 
hand, dHPLC is based upon similar statistical mechanical calculations of the transition 
temperature of DNA but has to accurately control the mobile phase and column temperature 
[184].
The costs of fluorescently labelled primers for use in PCR are another major factor in large-
scale projects requiring mutation analysis in hundreds or thousands of samples.
We have therefore designed and developed a single, universal priming system for the highly 
specific labelling of DNA amplification products. The procedure is based on a triplex-
primed PCR, employing two genome, or template, specific primers and a third labelled, 
universal primer. The advantage of this design is the reduction in time required to obtain 
labelling primer sets, the cost of primer sets, and the efficient use of labelled primers where 
only a limited number of genotyping applications per locus may be required. 
Benesova-Minarikova,L. et al. [185] have shown a simple approach to detection of 
unlabeled DNA fragments through intercalation without a need for adding intercalator to the 
separation polymer matrix on a MegaBACE 1000. 
The sensitivity is an important factor in all molecular techniques used for detection of low 
fraction mutations. The sensitivity of the DCE method was evaluated by mixing mutant and 
normal alleles in different ratios (paper I). The areas under the peaks were used as a 
quantitative measurement of the mutant fraction in the samples, as described earlier [90]. 
Loss of signal from the heteroduplex peaks was observed for mutant fractions below 
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4 x 10-3. The sensitivity found is in agreement with the sensitivity reported for automated 
CDCE [107;120], and this sensitivity should be sufficient in many areas of mutation and 
SNP detection/analysis. The practical confirmation of this method, detection of k-ras
mutations in tumours and lavage fluid was accomplished in paper V. In comparison 
sequence analysis of tumour DNA is a widely applied method, and is considered a direct 
and reliable approach. However, DNA sequencing has several disadvantages; the most 
notable of these is the low detection rate (25%). Samples containing large fractions of 
normal and fibrous tissues will interfere with accurate sequence analysis with respect to 
mutation detection. Direct sequencing of such samples will not reveal the mutated sequence 
since the detection limit is insufficient, and thus makes it difficult to identify the mutated 
alleles. It is therefore important to develop a method capable of immediately identifying the 
mutation without the need for sequencing. Bjørheim et al [111] have previously described a 
method  for direct identification of oncogenic mutants in K-ras exon 1 with the DCE 
method.  
Future Instrumentation perspectives  
In this thesis the value of DCE method in terms of sensitivity, specificity, simplification and 
throughput has explicitly been described. However several approaches can be used to 
further increase the throughput capacity of this method. First, several fluorophores with 
different wavelength can be used in the same electhrophoretic run. The capillary instruments 
have four channels for registration of emitted light; only two of the channels were used in 
the experiments reported in this thesis. Secondly this method can easily be adapted to a fully 
automated setup with the Caddy™, a robotic sample plate manipulator used together with 
the MegaBACE™ genetic analyzer [186]. And a throughput of more than 25 000 samples 
weekly is accomplished with a MegaBACE 4000 (384 capillaries) [187]. Furthermore 
development of a capillary instrument with 10 000 capillaries is under construction, and 
comprehensive scanning of all (25 000) genes for DNA variation will be possible in
1 000000 people [140]. 
Discovery of mutants with allele frequency less than 0.1% in a multicapillary instrument 
places great demands on sensitivity and dynamic range. With some improvements in optical 
detection the commercial multicapillary DNA sequencer together with fraction collection 
further facilitates the discovery of extremely low frequency alleles. Several groups have 
previously reported methods for fraction collection both in single and multicapillary 
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systems. However commercial multicapillary DNA analyzers are not yet equipped with 
automated fraction collection capabilities. This improvement of the automated capillary-
based fraction collection system could lead to high-throughput mutation detection by 
heteroduplex analysis or constant denaturant capillary electrophoresis. 
Conclusion
DCE methods were adapted for use with commercially available single-and multi-capillary 
instruments. The adaption of the DCE method to commercially single and multicapillary 
instruments has accomplished a high throughput method for detection of DNA variation. 
This method has shown to be cost-efficient, with high sensitivity and specificity. In this 
thesis we have shown that the method has several different applications, and that it is a 
feasible method to detect different key mutations and polymorphisms, which can affect 
outcome in cancer patients, as well as the pharmacogenetics of chemoprevention trials. 
Further perspectives 
A large number of cellular oncogenes have been identified in human tumours, including 
rectal cancer. To date there is no genetic marker that gives accurate information on the 
prognostic impact for patients with rectal cancer. New analyses of other mutations or 
combinations of genes that are specific for rectal carcinoma might lead to better candidates. 
On the basis of recent changes in genomics and high-throughput genotyping platforms, 
future genetic findings of association studies could have an impact on clinical care and 
public health screening. 
The variability in treatment responses and narrow therapeutic index of anticancer drugs are 
some of the key challenges oncologists face. The identification of genetic variations that 
predict for drug response is the first step towards the translation of pharmacogenetics into  
clinical practice. 
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